Meet with... NCATS

Add this event to your calendar:
05/11/2014 11:00 05/11/2014 14:00 America/New_York Meet with... NCATS MassBio HQ , 300 Technology Square, 8th Floor , Cambridge , MA 02139 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY
November
5
Event

Meet with... NCATS

MassBio HQ , 300 Technology Square, 8th Floor , Cambridge , MA 02139

November 05, 2014 from 11:00 AM to 14:00 PM (EDT)

$10 - $35


J-LABS BOSTON EVENT Translation is a team sport and NCATS wants to play

Program Overview:
Meet with the newest institute at the NIH called The National Center for Advancing Translational Science (NCATS). By design, NCATS was formed to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster.

NCATS directly addresses the obstacles scientists face when developing a novel drug, device or other intervention. They are committed to uncovering new technologies and other approaches that could greatly accelerate the development and deployment of solutions that all translational researchers can use.

The NCATS approach is distinct in many ways and has already made a significant impact. Successes include 19 INDs that have been cleared by the FDA, twelve projects have been evaluated in clinical trials, and three agents have gone as far as Phase II human clinical trials. Additionally, third-party investors have licensed seven agents that have been developed through NCATS programs.

Join us to learn more about NCATS and their innovative approach. Following an overview of NCATS' opportunities and key areas of interest, don't miss the opportunity to introduce yourself during the networking lunch. Finally, for those companies who applied online and were approved, one-on-one meetings with NCATS will provide a forum to further discuss your company.

NCATS is seeking to collaborate with companies focusing on translating bench top discoveries to clinical hypothesis testing.

Agenda:
10:00 AM | Registration & Networking
10:30 AM | Presentation & Q&A
12:00 PM | Lunch & Networking
1:00 PM | One-on-one Meetings*
4:30 PM | Program Close

*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period has closed on October 15.

NIH NCATS Participating Representative:
Nora Yang | Director of Portfolio Management and Strategic Operations , National Center for Advancing Translational Sciences, National Institutes of Health read bio»

About the National Center for Advancing Translational Sciences :
The National Center for Advancing Translational Sciences (NCATS) is the newest of 27 Institutes and Centers (ICs) at the National Institutes of Health (NIH). This Center was established in December 2011 to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Read more about NCATS»

Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until November 4 (or full).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period has closed on Wednesday, October 15, 2014. Your application will be reviewed and you will be notified of acceptance on Wednesday, October 29, 2014. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.

Location:
MassBio MassBio HQ
300 Technology Square, 8th Floor
Collaboration Room
Cambridge, MA 02139
Directions»

NIH NCATS Representative's Biography:
Nora Yang | Director of Portfolio Management and Strategic Operations , National Center for Advancing Translational Sciences, National Institutes of Health
Nora Yang is the Director of Portfolio Management and Strategic Operations at the National Center for Advancing Translational Sciences (NCATS), NIH. In her current role, Nora Yang is responsible for planning, identifying and managing collaboration opportunities and partnerships, developing new business models to improve efficiency and effectiveness of translational sciences, building portfolio and project management capabilities, and implementing best practices of managing public and private partnerships for the NIH National Center for Advancing Translational Sciences (NCATS). She took a leadership role in building and managing the rare and neglected disease drug development portfolio within NCATS, which has taken 4 investigational drugs into rare disease patients in 7 clinical trials within 3 years. Within 4 years, 3 assets within the portfolio have been acquired by pharma partners with a collective deal value of US$1.12 billion. Prior to joining NCATS at NIH, Dr. Yang led global product development teams to manage and develop novel therapeutics for metabolic diseases and oncology indications at Eli Lilly & Co. and Amgen, Inc. She also worked with startup companies and VC firms to build and evaluate business plans and raise series A funding for startup companies. Nora holds a Ph.D. in chemistry from the Salk Institute of biological Research and the University of California, San Diego, and a Master’s degree in business management from Stanford University, Graduate School of Business.



About the Meet with... Series:
The purpose of the Meet with Series events sponsored by J-Labs is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, New Enterprise Associates, and Thomas McNerney & Partners.


Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact


Related content